ClinicalTrials.gg
RecruitingNCT06183255Updated Dec 27, 2023

"System Medicine" Approach for Prevention Strategies for Comorbidities in Infertile Men

An observational study in Infertility and Male Infertility, sponsored by IRCCS San Raffaele. Recruiting at 1 site in Italy. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-12-27.

Primary conditionInfertility, MaleRegistry: InfertilityReclassifiedWhy we changed it
Registry
Infertility — the first condition term the registry derived for this study.
ClinicalTrials.gg
Infertility, Male
Why
  1. The study's listed conditions name Infertility, Male, a narrower term within Infertility.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by IRCCS San Raffaele · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Jul 2025, 1 year 4 months ago, but the record still lists the study as recruiting.
  • Started Jan 2021; still recruiting 5 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
200
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 17 studies in Infertility, Male with a site in Italy — 9 open to participants now, 9 under way, none of them phase 3. Infertility, Male · Italy.

Planned enrollment
7th of 10
200 · median 575
Started
2021
the only one that year
Observational
10 of 17
7 open now
Registered
12th of 17
by date
Lead sponsor
6 of 17
IRCCS San Raffaele

Among the 17 studies in Infertility, Male with a site in Italy, this one is the 7th largest by planned enrollment of the 10 observational ones that give a count, is the only one that started in 2021, is one of 10 observational ones, and was the 12th registered.

Infertility, Male

283 studies on the registry are indexed under Infertility, Male; 65 are open to participants now.

Browse Infertility, Male studies →

Open to participants now

9 of the 17 studies in Infertility, Male with a site in Italy are open now. Recruiting first, the newest first:

3 more — sign in →

All 9 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 41 Infertility, Male studies recruiting now, 17 (41%) set no upper age limit and 24 (59%) stop at 75 or younger; 8 take children under 18; 15 take healthy volunteers.

This study: 18 Years and older · male.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Infertility, Male with a site in Italy, or all of them as a file.
02

Study summary

By applying a "system medicine" approach, the project aims to identify new biomarkers and/or prognostic tools aimed at developing personalized strategies to prevent the onset of comorbidities in infertile men.

Read the detailed description

By applying a "system medicine" approach, the project aims to identify new biomarkers and/or prognostic tools aimed at developing personalized strategies to prevent the onset of comorbidities in infertile men.

The findings will provide new insights into the relationship between male infertility and somatic health, and shed light on the role of the microbiome in modulating the activity of the immune system. A "signature" of lack of immunological tolerance and biomarkers could be useful to predict future oncologic and non-oncological comorbidities in infertile men. This will let the development of a more clinically reliable and cost-effective personalized primary/secondary prevention strategy in a population at high risk of clinically relevant diseases.

03

Conditions studied

  • Infertility
  • Male Infertility

Browse trials for

Keywords

  • Infertility
  • Male Infertility
  • Comorbidity
04

In context

Infertility, Male Reclassified

283 studies on the registry are indexed under Infertility, Male; 65 are open to participants now.

This study's planned enrollment of 200 is close to the median of 182 across 87 observational studies indexed under Infertility, Male.

Browse Infertility, Male studies →

Lead sponsor

IRCCS San Raffaele is the lead sponsor of 458 studies on the registry; 237 are open to participants now.

Compared within Infertility, Male, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Infertility. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Sampling method
Non-probability sample

Study population

Fertile and infertile men according to WHO criteria (2010)

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signature of the ;
  • Be adults aged > 18;
  • Caucasian race;
  • Documented diagnosis of primary male infertility with pure male factor;

Exclusion criteria

Exclusion Criteria:

  • Failure to obtain ;
  • Patients with a known history of haematological disease;
  • Patients undergoing antibiotic treatments in the last 6 months
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

06

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
200 participants (estimated)
Patient registry
No

Groups and cohorts

  • Infertile men

    Men with a diagnosis of pure Male Factor Infertility, as for WHO criteria

    Other: Observation and evaluation of clinical parameters in the two cohorts

  • Fertile men

    Fathers with at least one child, spontaneously conceived, with a time-to-pregnancy within 12 months, as for WHO criteria

    Other: Observation and evaluation of clinical parameters in the two cohorts

Interventions

  • OtherObservation and evaluation of clinical parameters in the two cohorts

    During medical history evaluation, all factors that could negatively affect male fertility, like prevalent comorbidities, previous testis surgery, and any disorder affecting testicular function will be investigated in fertile and infertile men. Moreover, family history will be deeply investigated, including fertility status and prevalence of malignant Non Communicables Diseases. A comprehensive physical examination will be performed on each infertile and fertile man.

07

What researchers measure

Primary outcomes

  1. Medical anamnesis

    Data collection on Charlson Comorbidity Index (CCI), partner's age, partner's health status;

    Time frame: Baseline

  2. Objective examination

    presence of varicocele; testicular size and number

    Time frame: Baseline

  3. Testosterone

    data on testosterone (ng/dL)

    Time frame: Baseline

  4. Genetic profile

    Data on karyotype and microdeletions of the Y chromosome

    Time frame: Baseline

  5. Semen volume

    Semen volume (ml)

    Time frame: Baseline

  6. Body mass index

    Dataon Body mass index

    Time frame: Baseline

  7. Follicle-stimulating hormone

    Data on follicle-stimulating hormone (mIU/ml)

    Time frame: Baseline

  8. Luteinizing hormone

    Data on luteinizing hormone (mIU/dl)

    Time frame: Baseline

  9. Anti-Müllerian hormone

    Data on Anti-Müllerian hormone (ng/ml)

    Time frame: Baseline

  10. Inhibin B

    Data on Inhibin B (UI/mL)

    Time frame: Baseline

  11. Prolactin

    Data on Prolactin (µg/l)

    Time frame: Baseline

  12. Thyroid-stimulating hormone

    Data on thyroid-stimulating hormone (mU/L)

    Time frame: Baseline

  13. Osteocalcin levels

    Data on osteocalcin levels (ng/ml)

    Time frame: Baseline

  14. Semen concentration

    number of spermatozoa (million/ml)

    Time frame: Baseline

  15. Spermatozoa motility and morphology

    motility and morphology of spermatozoa (%)

    Time frame: Baseline

08

Study locations

1 of 1 sites recruiting
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2021 (actual). Primary completion is estimated for Jul 2025, 54 months after the start.

Of 40 observational studies under Infertility, Male, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 129. This study's planned 54 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 5, 2023
First posted
Dec 27, 2023
StartActual
Jan 18, 2021
Primary completionEst.
Jul 2025
CompletionEst.
Jul 2025
Last update
Dec 27, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 27, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06183255
Lead sponsor
IRCCS San Raffaele
Responsible party
Andrea Salonia (Professor, IRCCS San Raffaele) — Principal investigator
First posted
Dec 27, 2023
Start date
Jan 18, 2021
Primary completion
Jul 2025 (estimated)
Completion
Jul 2025 (estimated)
Last update
Dec 27, 2023

Study contacts

Andrea Salonia, MD
Contact
salonia.andrea@hsr.it
02 2643 5661
Alessia d'Arma, PhD
Contact
darma.alessia@hsr.it
02 2643 5506
Andrea Salonia, MD
principal investigator · IRCCS Ospedale San Raffaele

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion